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Objective: The aim of this study was to evaluate by clinical and laboratory parameters 
how cystic fibrosis (CF) affects growth and nutritional status of children who were under-
going CF treatment but did not receive newborn screening.
Methods: A historical cohort study of 52 CF patients younger than 10 years of age were 
followed in a reference center in Campinas, Southeast Brazil. Anthropometric measure-
ments were abstracted from medical records until March/2010, when neonatal screening 
program was implemented. Between September/2009 and March/2010, parental height 
of the 52 CF patients were also measured.
Results: Regarding nutritional status, four patients had Z-scores ≤–2 for height/age (H/A) 
and body mass index/age (BMI/A). The following variables were associated with impro-
ved H/A ratio: fewer hospitalizations, longer time from first appointment to diagnosis, 
longer time from birth to diagnosis and later onset of respiratory disease. Forced vital 
capacity [FVC(%)], forced expiratory flow between 25-75% of FVC [FEF25-75(%)], forced 
expiratory volume in the first second [FEV1(%)], gestational age, birth weight and early 
respiratory symptoms were associated with improved BMI/A.
Conclusions: Greater number of hospitalizations, diagnosis delay and early onset of res-
piratory disease had a negative impact on growth. Lower spirometric values, lower ges-
tational age, lower birth weight, and early onset of respiratory symptoms had negative 
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impact on nutritional status. Malnutrition was observed in 7.7% of cases, but 23% of 
children had nutritional risk.
© 2014 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
Fatores de impacto sobre o crescimento e o estado nutricional de pacientes com 
 fibrose cística menores de 10 anos que não foram submetidos à triagem neonatal
Resumo
Objetivo: O objetivo deste estudo foi avaliar por meio de parâmetros clínicos e labora-
toriais como a fibrose cística (FC) afeta o crescimento e estado nutricional de crianças 
que foram submetidas ao tratamento para FC, mas não receberam o diagnóstico pela 
triagem neonatal.
Métodos: Uma coorte histórica com 52 pacientes com FC menores de 10 anos de idade foram 
acompanhados em um centro de referência em Campinas, Sudeste do Brasil. Peso e altura 
foram coletados de prontuários médicos até março de 2010, quando a triagem neonatal foi 
implementada. Entre setembro de 2009 a março de 2010 a altura dos pais foi mensurada.
Resultados: Quatro pacientes tiveram escores Z≤–2 para altura/idade (A/I) e índice de 
massa corporal/idade (IMC/I). Foram associados com melhor A/I: menor número de hos-
pitalizações, maior tempo entre a primeira consulta e o diagnóstico, maior tempo entre 
o nascimento e o diagnóstico e início tardio da doença respiratória. Capacidade vital 
forçada [CVF(%)], fluxo expiratório forçado entre 25-75% da CVF [FEF25-75(%)], volume 
expiratório forçado no primeiro segundo [VEF1(%)], idade gestacional, peso ao nascer e 
início sintomas respiratórios foram associados com melhor IMC/I.
Conclusões: Maior número de hospitalizações, retardo no diagnóstico e início precoce da 
doença respiratória tiveram impacto negativo no crescimento. Menores valores espiro-
métricos, menor idade gestacional, menor peso ao nascer e o início precoce dos sintomas 
respiratórios tiveram impacto negativo no estado nutricional. A desnutrição foi observada 
em 7,7% dos casos, mas 23% das crianças apresentaram risco nutricional.










Cystic fibrosis (CF) is an autosomal recessive disease that is 
highly prevalent among caucasians. CF is characterized by 
the involvement of multiple organs, especially the pulmo-
nary and gastrointestinal systems; by abnormally high lev-
els of sweat chloride, and by increased incidences of male 
infertility and diabetes mellitus.1
Dietetic care is needed and individualized attention should 
be given to ensure adequate energy intake among CF 
patients. To maintain adequate nutritional status, CF chil-
dren should ingest 110 to 150% of the daily caloric intake 
recommended for healthy children.2 Pancreatic insufficiency 
with chronic malabsorption, recurrent infections, chronic 
inflammation and energy expenditure, and insufficient nutri-
tional intake are factors exacerbating malnutrition in CF 
patients. These factors lead to difficulties with weight main-
tenance and weight gain, and failure to thrive in infancy.
Regardless of the origin and reasons for high energy expen-
diture, the more clinically pertinent question is the influence 
of nutrition on the progression of lung disease, because lung 
function in CF patients is the main predictor of survival.3,4 
Clinical studies indicate that nutritional status plays an 
important role in the progression of lung disease in CF and it 
is a survival advantage among patients with good nutritional 
status.3,4 These studies consistently support the strong influ-
ence of growth and nutritional status on CF-associated lung 
disease. But from birth, nutritional deficiency is determined 
primarily by pancreatic insufficiency and malabsorption, so 
subsequent aggressive nutritional support should facilitate 
proper growth and preserve lung function.
In Brazil, CF is associated with high morbidity and mor-
tality. However, the survival of affected children in Brazil 
has increased substantially in the last 50 years due to an 
interdisciplinary approach to treatment, new medications 
and progress related to nutritional intervention and con-
trol. During the past 20 years, the benefit of early diagnosis 
on the nutritional status of CF patients has been estab-
lished.5,6 However, failure-to-thrive diagnoses remain com-
mon despite early identification of CF.7,8
In this study, we use clinical and laboratory variables to 
assess how CF affects the growth and nutritional status of 
patients younger than 10 years who were undergoing CF 
treatment but did not receive newborn screening. 
Method
A historical cohort study was designed to evaluate CF 
patients younger than 10 years from the CF Reference 
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onset of gastrointestinal and respiratory symptoms in 
months, number of hospitalizations per year, hepatopathy 
and pancreatic insufficiency.
Pulmonary function by spirometry test was performed 
in all CF patients with seven years of age, and the data 
was collected yearly until ten years of age. The fat bal-
ance and pulmonary microbiological data were collected, 
at the first appointment, at the reference center at diag-
nosis and annually during each patient’s birthday month. 
Indicators were obtained a maximum of two months 
before or two months after the collection of anthropo-
metric measurements. 
Pulmonary function was assessed by spirometry in chil-
dren older than seven years. We used a model CPFS/D spi-
rometer (MedGraphics, Medical Graphics Corporation®, MN, 
USA) and the spirometry software BREEZE PF version 3.8 B 
for Windows 95/98/NT (Medical Graphics Corp., MN, USA). 
During the test, the following parameters were evaluated: 
forced vital capacity (FVC), forced expiratory volume in the 
first second (FEV1), the Tiffenau Index (FEV1/FVC ratio) 
(TIFF) and forced expiratory flow between 25-75% of the 
FVC (FEF25-75%). The results followed the recommendations 
of the European Respiratory Society (ERS) and the American 
Thoracic Society (ATS),16 and all values were compared with 
the Polgar and Promadaht17 data and the absolute number 
was achieved for each patient included in the study. The 
values from the spirometry test were not adjusted by cat-
egories considering the severity. The absolute values of the 
data were considered, using numerical distribution to data 
analyses.4
The Van der Kamer method18 was used to assess fecal fat 
balance. Results were considered abnormal when fecal fat 
exceeded 2g/day in children aged 12 years or younger, or 
5g/day in patients older than 12 years. The fecal fat bal-
ance was used to diagnose pancreatic insufficiency. 
Patients were also classified according to pulmonary col-
onization and infection by Pseudomonas aeruginosa.19
The SAS System for Windows version 9.1.3 (SAS Institute 
Inc.; Cary, NC, USA) was used for statistical analysis. To 
examine the relationship between the evolution of 
weight/height and CF complications, generalized estimat-
ing equations (GEE)20 were applied to data from the same 
patient at different times. The variables were transformed 
into ranks due to the lack of a normal distribution. The 
significance level was set at p<0.05. The study was 
approved by the Ethics Committee of the School of Medical 
Sciences from State University of Campinas (#539/2008). 
The guardians of the patients gave written consent before 
the study began. 
Results
The study population included 52 CF patients. Of these, 
27/52 (51.9%) were female, and 49/52 (94.7%) were cauca-
sian. The average patient age was 6 years and 9 months 
(±2,40). 
Regarding mutations in the CFTR gene, 26/52 (50%) car-
ried two known CF-associated alleles, 21/52 (40.4%) car-
ried one known allele, and 5/52 (9.6%) had no known 
alleles. Mutations were detected at the following frequen-
Center of the Hospital of Clinics of the University of 
Campinas (Unicamp, SP, Brazil). CF diagnoses were made 
when two sweat tests exceeded 60mEq/L for chloride and/
or by genetic analyses with the identification of two CFTR 
mutations. Anthropometric measurements data weight and 
height were taken from medical records until March 2010, a 
time prior to the neonatal screening implementation, at the 
following times: birth, the first appointment with a medical 
specialist, at diagnosis and annually during each patient’s 
birthday month. Between September 2009 and March 2010, 
parental heights also were measured. Patient weights were 
determined to the nearest 0.1kg using a digital electronic 
scale (Filizola®) with a 150kg capacity and 100 g accuracy. 
Heights were measured to the nearest 0.1cm using a wood-
en stadiometer. For children younger than 24 months, body 
length was measured with a horizontal child anthropometer. 
Clinical measurements were conducted in accordance with 
the Anthropometric Standardization Reference Manual.9 
Z-scores were calculated for anthropometric indices includ-
ing height/age (H/A) and body mass index/age (BMI/A) for 
all subjects. 
Z-score calculations were made using the programs WHO 
Anthro10 for children younger than five years and WHO Anthro 
PLUS11 for children aged five years and older. Nutritional sta-
tus was classified according to anthropometric indices using 
the classification of the World Health Organization (WHO).12,13 
Parental heights were measured to the nearest 0.1cm using 
a wooden stadiometer with an extension of 200cm displayed 
on a flat, vertical surface. Parental heights were trans-
formed using the SISCRES program (Sistema de Análise do 
Crescimento – Growth Analysis System) into a distribution of 
Z-scores to obtain the mean and standard deviation based on 
CDC (Centers for Disease Control and Prevention) 2002 
growth charts.14 Birth weights were classified according to 
WHO criteria.15
The nutritional treatment offered by this Reference 
Center is performed by a team composed of a dietitian and 
a physician specialized in nutrition. The state of São Paulo 
has offered free dietary supplements when prescribed by a 
doctor or dietitian to CF patients since 2003. At the first 
moment that weight and height progress is unsatisfactory, 
according to the current guidelines,2 oral supplements are 
usually advised. The enteral tube feeding is an option if the 
weight/height ratio falls below 85%, or even after trying 
oral energy supplements. Fat-soluble vitamins are always 
prescribed, and pancreatic enzymes are administered if 
there is evidence of pancreatic insufficiency. Vitamins and 
enzymes as well as drugs prescribed are offered by the 
State of São Paulo government.
Regarding genetic study, data were abstracted from 
medical records for the following CF-associated muta-
tions: F508del, G542X, N1303K, G551D, R553X, and 
R1162X. Patients were classified as harboring two known 
CF alleles, one known allele, or no known allele. CFTR 
mutations were identified by polymerase chain reaction 
for the F508del mutation, and by the fragment-length 
polymorphism method for the G542X, R1162X, R553X, 
G551D and N1303K mutations. All CFTR mutations are 
included in classes I, II or III.
Patient medical records were reviewed for data regard-
ing exclusive breastfeeding, presence of meconium ileus, 
6 Russo Hortencio TD et al
cy: F508del/F508del, 17 patients; F508del/G542X, five 
patients; F508del/N1303K, one patient; F508del/R1162X, 
two patients; F508del/R553X, one patient; F508del/no 
identified mutation, 19 patients; G542X/no identified 
mutation, one patient; R1162X/no identified mutation, one 
patient, and no identified mutation/no identified muta-
tion, five patients. 
The median time between birth and diagnosis was 22 
months (0-106.6 months). The median time of onset of gas-
trointestinal symptoms was 8 months (0-187.3 months), and 
the median time to respiratory symptoms was 14 months 
(0-223.1 months). The median time between the first visit 
in the service and the diagnosis was 2.4 months (0-66.8 
months). 
Of the patients surveyed, 18.6% were born preterm, and 
23.5% were born weighing <2.5kg. The mean birth weight 
was 2.9±0.6kg, the mean length was 47.5±2.6cm, and the 
mean duration of exclusive breastfeeding was 3.3±2.9 
months. 
Meconium ileus, liver abnormalities and pancreatic insuf-
ficiency were present in 23%, 40% and 90.8% of patients, 
respectively. The patients had an average of 1.5 hospital-
izations and a median of one hospitalization during the 
study period. Regarding lung infection/colonization, 64.3% 
of patients were chronically colonized by P. aeruginos,a 
and 69.2% had been submitted to spirometry. 
Patient’s mothers and fathers had an average height of 
1.62m and 1.73m, respectively. The parental target Z-score 
achieved by patients averaged 0.93. At birth, 25% of 
patients had Z-scores <–2 according to the H/A index, and 
21% had Z-scores <–2 according to the BMI/A index. At their 
first appointment in the service, 38% of patients had 
Z-scores <–2 according to the H/A index. According to 
BMI/A, 40.4% had Z-scores <–2. At diagnosis, 32% of patients 
exhibited Z-scores <–2 according to the H/A, versus 7.7% in 
the current anthropometry (Table 1). Regarding BMI/A, 21% 
of patients had Z-scores <–2 at diagnosis, versus 7.7% in the 
current anthropometry (Table 2).
Table 3 shows the results for the estimation obtained by 
GEE for the H/A index. Better correlated H/A values were 
related to fewer hospitalizations, greater time between the 
first appointment and diagnosis, greater time between birth 
and diagnosis and later onset of respiratory symptoms.
Table 4 summarizes the results of the GEE analysis for the 
BMI/A index. Better correlated BMI/A values were associated 
with higher FVC, FEV1, FEF25-75% values; longer gestational age; 
greater birth weight, and later onset of respiratory symptoms.
Discussion
The age at diagnosis is an important factor for the nutri-
tional status of CF patients. Early diagnosis facilitates spe-
cial attention to nutritional status, growth curve monitor-
ing and detection of pathogen colonization in upper air-
ways, which is intimately related with a worse prognosis. 
On this historical cohort, we discuss about how CF manifes-
tations can affect the growth and the nutritional status of 
affected children.
Patients diagnosed early are closer to normal nutritional 
status at diagnosis and during the following 10 years.5 In 
this study, the median time between birth and diagnosis 
was 22 months, and the median time between the first 
appointment and diagnosis was 2.4 months. 
North American and European data report median ages 
at CF diagnosis of six months and five months, respective-
ly.21,22 Late CF diagnosis occurs in developed countries 
among patients with distinct genotypic expression, milder 
pulmonary disease and absent gastrointestinal symptoms.23 
In a developing country like Brazil, aside from the afore-
mentioned reasons, delayed diagnosis appears to result 
from late forwarding of patients to a reference center, 
because the disease is not immediately recognized. 
In our study, longer times between birth and diagnosis 
and between the first appointment and diagnosis were 
associated with better correlated H/A; moreover, delayed 
respiratory symptom onset was associated with better H/A 
and BMI/A ratios. These associations are probably due to 
the presence of patients with mild lung disease and no sug-
gestive symptoms of CF, and consequently, a smaller impact 
of the disease on growth and nutritional status, as it is 
known that improvement in pulmonary function is associat-
ed with increased BMI during childhood.24
There was improved nutritional status with increased 
FVC(%), FEV1(%) and FEF25-75% values, as analyzed by the 
BMI/A index. 
According to the literature, lung health depends on the 
patient’s initial nutritional status. Patients who recover 
from poor nutritional status up to two years after the diag-
nosis show better pulmonary function and less coughing at 
Table 1 Nutritional status of 52 CF patients aged less than 10 years according to gender and H/A index.




<–3 Z-Score 2 3.8 1/1 3.7/4.0
≥–3 Z-Score and <–2 Z-core 2 3.8 1/1 3.7/4.0
≥–2 Z-Score and <–1 Z-Score 16 30.8 9/7 33.3/28.0
≥–1 Z-Score and ≤+1 Z-Score 26 50.0. 12/14 44.4/56.0
>+1 Z-Score and ≤+2 Z-Score 5 9.6 4/1 14.8/4.0
>+2 Z-Score and ≤+3 Z-Score 1 1.9 0/1 0/4.0
>+3 Z-Score 0 0. 0/0 0/0
n, number of patients; %, percentage; M, male; F, female; H/A, Height/Age.
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six years of age, emphasizing the need for comprehensive 
and aggressive treatment, implemented as soon as possible 
after diagnosis.25 
Weight and height changes have been recognized as one 
of the prognostic factors of severity of the disease and 
shorter survival in CF patients. A limitation of our study is 
that spirometry was done on patients older than seven 
years old, not including the entire CF patient population. 
The incidence of low height and weight decreased during 
treatment in this study. At the first appointment in the 
service, 40.4% of patients had Z-scores <–2 according to the 
BMI/A index, versus 7.7% of patients assessed before the 
neonatal screening implementation. As for the H/A index, 
38% of patients had Z-scores <–2, versus 7.7%. 
The high percentage of CF patients with meconium ileus 
(23%) could justify the high percentage of patients who 
were malnourished in their first years of life. Patients with 
meconium ileus treated surgically in the first days of life 
undergo aggravating effects that can impair their nutrition-
al status, and the surgical stress may difficult feeding post-
operatively, during an important phase of growth. But these 
patients had a good nutritional recovery without compro-
mising their nutritional status and growth. Due to improve-
ments in neonatal surgical techniques, better postopera-
tive care and nutritional support, the nutritional status and 
survival of CF patients with meconium ileus appear to be 
similar to those of CF patients without meconium ileus. The 
incidence of meconium ileus reported by Alvarez et al, at 
the same CF Reference Center, was 5.8%.23 The hypothesis 
associated with the low incidence of meconium ileus in the 
last study was that CF patients would die in the first year 
of life, before the diagnosis was performed.23 In the pres-
ent study, we detected meconium ileus in 23% of patients, 
a value close to the 15-20% mentioned in the international 
literature.26 Currently, with the neonatal screening, the 
management of meconium ileus may be more effective in 
patients with CF.
Height is an inherited growth trait deeply influenced by 
nutrition and diseases. Parents of CF patients had higher 
average heights compared with the average population. 
Average heights were 1.73m for fathers and 1.62m for 
mothers in the present study. 
According to the Brazilian Institute of Geography and 
Statistics (IBGE), the average height of Brazilian men was 
1.70m, and of Brazilian women was 1.58m in 2009.27 The 
genetic contributions of parents to the height of their off-
spring are influenced by nutrition and diseases, especially 
chronic diseases such as CF. The height of the studied 
patients, considering the parental target, was adequate. 
This is incongruent with data obtained by other studies that 
reported a decreased average height among CF children 
compared with average parental height.28 Thus, despite 
late diagnoses (median of 22 months in this study versus six 
months in developed countries), the final heights of the 
children in this study were not impaired, which probably 
reflects the appropriate multidisciplinary care offered to 
patients. These data indicate that the nutritional status of 
our patients may have been similar to those obtained in 
major centers in developed countries.
A child with a Z-score ranking in the range ≥–2 and <–1, 
suggesting that the child is approaching categories of low 
weight or height for their age, deserves the attention of 
health professionals and caregivers. A child with this range 
should be considered as risk group for nutritional monitor-
ing. In this study, 30.8% of patients according to the H/A 
index and 23% of patients according to the BMI/A index 
were within this monitoring range of nutritional risk. It is 
noteworthy that most patients were of adequate height 
and weight, according to the studied indices, but weight 
changes in CF are very frequent, requiring special attention 
to these events.
CF children have pancreatic insufficiency at birth. Low 
birth weight is present even in the absence of prematurity, 
as changes in fetal growth due to the malfunctioning exo-
crine pancreas reduce intrauterine nutrition and precipi-
tate lower birth weights.29 In our study, 23.5% of patients 
had low birth weight, and 18.6% were preterm infants. 
These values exceed those reported by Festini et al, who 
evaluated the neonatal characteristics of children with CF 
in Italy.30 They showed that the weights of newborns with 
CF are in average 246g lower than those of the non-CF pop-
ulation, and that CF children have a higher risk of being 
born preterm, small for gestational age and with a low 
birth weight than children without CF.30
Patients who are less often hospitalized have better H/A 
relationship. Among CF patients, the increased need for 
energy intake is associated with increased caloric demand 
due to repetitive airway infections and inflammation, 
decreased food intake during the episodes of acute respira-
tory disease and decreased fat absorption. This energy 
Table 2 Nutritional status of 52 CF patients aged less than 10 years according to gender and the BMI/A index.




<–3 Z-Score 2 3.8 0/2 0/8
≥–3 Z-Score and <–2 Z-core 2 3.8 2/0 8/0
≥–2 Z-Score and <–1 Z-Score 12 23.1 6/6 22/24
≥–1 Z-Score and ≤+1 Z-Score 30 57.7 14/16 52/64
>+1 Z-Score and ≤+2 Z-Score 5 9.6 5/0 18.5/0
>+2 Z-Score and ≤+3 Z-Score 1 1.9 0/1 0/4
>+3 Z-Score 0 0. 0/0 0/0
n, number of patients; %, percentage; M, male; F, female; BMI/A, body mass index/age.
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deficit causes or worsens malnutrition and is common in 
hospitalized patients. It leads to growth retardation, 
decreased muscle strength, fatigue, recurrent respiratory 
infections and diminished lung function, thereby decreas-
ing survival in CF patients.
Despite the high prevalence of preterm birth, low birth 
weight and P. aeruginosa colonization, the studied patients 
exhibited good nutritional status and growth during child-
hood. Probably, the treatment offered in our reference 
center is associated to this outcome. The Reference Center 
offers appointments with health professionals of four med-
ical specialties: pulmonology, gastroenterology, physiother-
apy and nutrition, and the state of São Paulo, in Brazil, 
offers free dietary supplements when prescribed by a doc-
tor or dietitian to CF patients since 2003. This policy has 
ensured better adherence to treatment and better nutri-
tion. Furthermore, a non-governmental organization 
formed by parents, called “Fibrocis”, works in tandem, 
Table 3 Relationship between clinical and laboratory CF variables and H/A index using generalized linear models with GEE 
(Generalized Estimating Equations).
Variables Estimate Standard error 95%CI p value
Pseudomonas aeruginosa
No 0.203 0.123 —0.038 0.444 0.099
Yes 0 0 0 0 —
Pancreatic Insufficiency
No 0.169 0.137 —0.099 —0.437 0.217
Yes 0 0 0 0 —
Hepatopathy
No 0.066 —0.123 —0.176 —0.308 0.593
Yes 0 0 0 0 —
Spirometry
FVC (%) —0.001 0.003 —0.007 0.005 0.788
FEV1 (%) —0.001 0.004 —0.009 0.006 0.749
FVC/FEV1 (%) —0.007 —0.007 —0.017 0.004 0.204
FEF25-75 (%) —0.002 —0.001 —0.004 —0.004 0.938
Gestational age
Term 0.177 0.128 —0.073 —0.428 0.166
Preterm 0 0 0 0 —
Birth weight
≥2.5kg 0.704 1.054 1.367 2.769 0.504
<2.5kg 0 0 0 0 —
Meconium ileus
Yes —0.091 0.122 —0.329 0.147 0.452
No 0 0 0 0 —
Period of exclusive breastfeeding
— 0.028 0.017 0.005 0.061 0.094
Number of hospitalizations
— —0.101 0.022 —0.144 –0.058 <0.001
Time from 1st appointment to diagnosis
 — 0.004 0.001 0.001 0.007 0.004
Time between birth and diagnosis
— 0.004 0.001 0.002 0.006 <0.001
Known alleles
1 known allele —0.023 0.131 —0.280 0.234 0.861
2 known alleles —0.044 0.146 —0.330 0.242 0.764
No known alleles 0 0 0 0 —
Onset of gastrointestinal symptoms
— 0.002 0.001 —0.001 0.004 0.161
Onset of respiratory symptoms
— 0.004 0.002 0.001 0.007 0.010
H/A, Height/age; FVC (%), forced vital capacity; FEV1 (%), forced expiratory volume in the first second; FEF25-75 (%), forced expiratory 
flow between 25-75% of FVC; CI, confidence interval.
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offering home visits made by social workers and financial 
assistance for patient transportation to appointments.
The present study is unique because it is the first to 
evaluate how several CF manifestations affect the growth 
and nutritional status of children who were undergoing CF 
treatment but were not diagnosed at birth by newborn 
screening in Brazil. However, there are several limitations. 
Although some results are based on a form filled by doctors 
responsible for these patients, some tests are not routinely 
Table 4 Relationship between clinical and laboratory CF variables and BMI/A index using generalized linear models with GEE 
(Generalized Estimating Equations).
Variables Estimate Standard error 95%CI p value
Pseudomonas aeruginosa
No —0.021 0.082 —0.182 0.140 0.799
Yes 0 0 0 0 —
Pancreatic Insufficiency
No —0.056 0.100 —0.251 0.139 0.573
Yes 0 0 0 0 —
Hepatopathy
No —0.071 —0.071 —0.091 —0.240 0.436
Yes 0 0 0 0 —
Spirometry
FVC (%) 0.008 0.003 0.003 0.013 0.002
FEV1 (%) 0.009 0.003 0.004 0.014 0.001
FVC/FEV1 (%) —0.001 0.005 —0.010 0.008 0.824
FEF25-75 (%) 0.004 0.002 0.001 0.007 0.008
Gestational age
Term 0.378 0.123 0.136 0.619 0.002
Preterm 0 0 0 0 —
Birth weight
≥2.5kg 0.479 0.115 0.255 0.703 <0.001
<2.5kg 0 0 0 0 —
Meconium ileus
Yes —0.118 0.111 —0.335 0.098 0.285
No 0 0 0 0 —
Period of exclusive breastfeeding
— 0.017 0.016 —0.014 0.047 0.281
Number of hospitalizations
— —0.022 0.027 —0.076 0.032 0.422
Time from 1st appointment to diagnosis
— 0.002 0.002 —0.002 0.005 0.294
Time between birth and diagnosis
— 0.002 0.001 —0.001 0.004 0.065
Known alleles
1 known allele 0.065 0.145 —0.224 0.355 0.657
2 known alleles 0.004 0.153 —0.254 0.346 0.763
No known allele 0 0 0 0 —
Onset of gastrointestinal symptoms
— 0.002 0.001 0 0.003 0.054
Onset of respiratory symptoms
— 0.002 0.001 0.001 0.004 0.014
BMI/A, body mass index/age; FVC (%), forced vital capacity; FEV1 (%), forced expiratory volume in the first second; FEF25-75 (%), forced 
expiratory flow between 25-75% of FVC; CI, confidence interval.
performed due to cost constraints and government funding 
restrictions. Another limitation is that data collection was 
performed at a single major center in Brazil, and our results 
may not reflect the nutritional status and growth of all 
Brazilian children with CF. 
In conclusion, several CF manifestations influenced 
growth and nutritional status during treatment, but these 
patients exhibited good nutritional status, with a low rate 
of malnutrition and adequate growth. However, many of 
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them were in the range of nutritional risk, requiring special 
attention to weight loss and proper growth. Appropriate 
nutritional management detemines outcomes. 
It is crucial that dietitians, pediatricians and other pro-
fessionals involved in the care of CF patients recognize the 
growth process of patients since the first appointment to 
allow for early intervention upon diagnosis, before signifi-
cant malnutrition occurs. Attention given at childhood can 
impact on nutritional status, growth, pulmonary health and 
treatment adherence, and it can enhance the survival and 
quality-of-life of patients with CF. 
Funding
This research was supported by Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior (Capes), 
Brazil.
Conflicts of interest
The authors declare no conflicts of interest.
Acknowledgments
The authors thank the interprofessional care team of the 
Hospital of Clinics of the University of Campinas-Unicamp, 
the patients and parents who participated in this study. The 
authors thank Helymar da Costa Machado for the statistical 
analysis.
References
1. Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza 
D, et al. An overview of international literature from cystic 
fibrosis registries. Part 4: update 2011. J Cyst Fibros. 2012; 
11:480-93.
2. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, 
Heijerman HG, et al. Nutrition in patients with cystic fibrosis: 
a European consensus. J Cyst Fibros. 2002;1:51-75.
3. Shoff SM, Tluczek A, Laxova A, Farrell PM, Lai HJ. Nutritional 
status is associated with health-related quality of life in 
children with cystic fibrosis aged 9-19 years. J Cyst Fibros. 
2013;12:746-53. 
4. Stephenson AL, Mannik LA, Walsh S, Brotherwood M, Robert R, 
Darling PB, et al. Longitudinal trends in nutritional status and 
the relation between lung function and BMI in cystic fibrosis: a 
population-based cohort study. Am J Clin Nutr. 2013;97:872-7. 
5. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns T, 
et al. Nutritional benefits of neonatal screening for cystic 
fibrosis. N Engl J Med. 1997;337:963-9.
6. Ranganathan SC, Parsons F, Gangell C, Brennan S, Stick SM, Sly 
PD. Australian Respiratory Early Surveillance Team for Cystic 
Fibrosis. Evolution of pulmonary inflammation and nutritional 
status in infants and young children with cystic fibrosis. Thorax. 
2011;66:408-13. 
7. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, et 
al. Lung disease at diagnosis in infants with cystic fibrosis 
detected by newborn screening. Am J Respir Crit Care Med 
.2009;180:146-52.
8. Assael BM, Casazza G, Iansa P, Volpi S, Milani S. Growth and 
long-term lung function in cystic fibrosis: a longitudinal study 
of patients diagnosed by neonatal screening. Pediatr Pulmonol. 
2009;44:209-15.
9. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization 
Reference Manual. Champaign: Human Kinetics; 1988.
10. World Health Organization. WHOAnthro [computer program]. 
Version 3.0.1. Geneva: WHO; 2006.
11. World Health Organization [homepage on the Internet]. 
Software for assessing growth of the world’s children and 
adolescents. Geneva: WHO; 2007 [accessed 1 April 2014]. 
Available from: http://www.who.int/growthref/tools/who_
anthroplus_manual.pdf.
12. World Health Organization [homepage on the Internet]. WHO 
child growth standards: methods and development: length/
height-for-age, weight-for-age, weight-for-length, weight-for-
height and body mass index-for-age. Geneva: WHO; 2006.
13. De Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann 
J. Development of a WHO growth reference for school-aged 
children and adolescents. Bull World Health Organ. 2007;5:660-7.
14. Centers For Disease Control and Prevention and National Center 
For Health Statistics [homepage on the Internet]. 2000 CDC 
growth charts: United States Hyaltsville [accessed 21 July 
2014]. Available from: http:// www.cdc.gov/growthcharts.
15. Autoria não referida. Physical status: the use and interpretation 
of anthropometry. Report of a WHO Expert Committee. World 
Health Organ Tech Rep Ser. 1995;854:1-452.
16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates 
A, et al. Standardisation of spirometry. Eur Respir J. 2005;26: 
319-38.
17. Quanjer PH, Borsboom GJ, Brunekreef B, Zach M, Forche G, 
Cotes JE, et al. Spirometric reference values for white 
European children and adolescents: Polgar revisited. Pediatr 
Pulmonol. 1995;19:135-42.
18. Van de Kamer JH, Ten Bokkel H, Weyers HA. Rapid method for 
the determination of fat in feces. J Biol Chem. 1949;177:347-55.
19. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, 
Molin S. Adaptation of Pseudomonas aeruginosa to the cystic 
fibrosis airway: an evolutionary perspective. Nat Rev Microbiol. 
2012;10:841-51.
20. Liang KY, Zeger SL. Longitudinal data analysis using generalized 
linear models. Biometrika. 1986;73:13-22.
21. Cystic Fibrosis Foundation [homepage on the Internet]. Patient 




22. UK CF Registry. Annual data report 2008. Kent: Cystic Fibrosis 
Trust; 2009. 
23. Alvarez AE, Ribeiro AF, Hessel G, Bertuzzo CS, Ribeiro JD. Cystic 
fibrosis at a Brazilian center of excellence: clinical and 
laboratory characteristics of 104 patients and their association 
with genotype and disease severity. J Pediatr (Rio J). 2004; 
80:371-9.
24. Yen EH, Quinton H, Borowitz D. Better nutritional status in 
early childhood is associated with improved clinical outcomes 
and survival in patients with cystic fibrosis. J Pediatr. 
2013;162:530-5.
25. Lai HJ, Shoff SM, Farrell PM; Wisconsin Cystic Fibrosis Neonatal 
Screening Group. Recovery of birth weight z-score within two 
years of diagnosis is positively associated with pulmonary 
status at age six years in children with cystic fibrosis. Pediatrics. 
2009;123:714-22.
26. Van der Doef HP, Kokke FT, van der Ent CK, Houwen RH. 
Intestinal obstruction syndromes in cystic fibrosis: meconium 
ileus, distal intestinal obstruction syndrome, and constipation. 
Curr Gastroenterol Rep. 2011;13:265-70.
Factors impacting the growth and nutritional status of cystic fibrosis patients younger than 10 years 11
27. Brasil – Ministério da Saúde; Instituto Brasileiro de Geografia e 
Estatística; Ministério do Planejamento, Orçamento e Gestão. 
Pesquisa de Orçamentos Familiares: antropometria e estado 
nutricional de crianças, adolescentes e adultos no Brasil. Rio 
de Janeiro: IBGE; 2010.
28. Zhang Z, Shoff SM, Lai HJ. Incorporating genetic potential 
when evaluating stature in children with cystic fibrosis. J Cyst 
Fibros. 2010;9:135-42.
29. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, 
Hambidge KM, et al. Pancreatic insufficiency, growth, and 
nutrition in infants identified by newborn screening as having 
cystic fibrosis. J Pediatr. 1992;120:533-40.
30. Festini F, Taccetti G, Repetto T, Reali MF, Campana S, Mergni 
G, et al. Gestational and neonatal characteristics of children 
with cystic fibrosis: a cohort study. J Pediatr. 2005;147:316-
20.
